Access to therapy is part of the protection of the constitutional order: Peter Bely spoke at the SPIEF session on intellectual property
21.09.2023
Medicines
21.09.2023
On September 19, 2023, Promomed Group of companies, one of the leaders of the Russian pharmaceutical market, held a press event dedicated to the launch of the innovative import-substituting drug Enligria (INN liraglutide) and an entire line of drugs for the treatment of patients with socially significant diseases such as diabetes mellitus 2 for example, overweight and obesity, as well as for the prevention of the development of cardiovascular complications associated with the above diseases.
The event was attended by prominent members of the medical community, as well as representatives of the Promomed Group of companies. They highly appreciated the importance of bringing the first drug of this class to the Russian market by a domestic manufacturer.Natalia Mokrysheva, Director of the National Research Institute of Endocrinology of the Ministry of Health of the Russian Federation, emphasized in her speech: "The endocrinological community welcomes the emergence of new drugs for the treatment of diabetes and obesity as part of import substitution. Fully Russian production of the drugs will ensure their continued availability to our patients, which is especially important given that therapy must be continuous."
According to Oksana Drapkina, Director of the NMC of Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation, , "in modern realities, when a shortage of similar foreign drugs has been artificially created, a new Russian-made drug with INN liraglutide is urgently needed in our country. The creation of this drug is logical and natural, and I would like to express the hope that this line of Russian drugs will be expanded in the near future, which will provide significant assistance in the treatment of patients with type 2 diabetes, overweight and obesity, as well as in the prevention of the development of cardiovascular complications associated with these diseases."i>.
In his introduction Peter Bely, Chairman of the Board of Directors of Promomed Group of Companies noted: "The development and market launch of the first domestic drug from the glutide line is an important step for our company. We are pleased to provide all doctors and patients in our country with the necessary amount of high-quality and effective medicine. I would like to express my gratitude to our colleagues, leading specialists and representatives of the scientific and medical community. Without close cooperation with them, this project could not have been implemented so productively and in such a short time."
The new line includes the drugs Enligria, Quinliro (INN liraglutide) and Quincenta (INN semaglutide). The drug under the trade name "Enligria", produced in the form of a pre-filled pen syringe, received a registration certificate the day before. Enligria will be delivered to pharmacies in the second decade of October this year. The drugs "Quinliro" and "Quincenta" are at the stage of state registration. The release of drugs is organized in partnership with the pharmaceutical company LLC "Plant "Medsintez".
About the drug
Liraglutide is one of the most modern drugs in the world for the treatment of type 2 diabetes and obesity. The pharmacological effects of liraglutide: controlled stimulation of insulin production, adaptive effects on glucagon activity, control of eating behavior – make it possible to achieve stable control of blood sugar levels in patients, facilitate adherence to rational eating habits, which ensures significant weight loss and the achievement of goals for the treatment of diabetes and obesity without compromising the quality of life of patients. Enligria is a liraglutide agonist of a glucagon–like peptide produced by chemical synthesis, which is 97% homologous in amino acid composition to human GLP–1 and resistant to degradation by body enzymes, which ensures long-term action. The use of the drug leads to an acceleration of the onset and prolongation of feelings of satiety, a decrease in hunger and the expected amount of food intake and correction of eating behavior, in general, and consequently, a marked weight loss and the preservation of achieved results.
— View the press release in PDF format
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
